Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Among authors: fuereder t. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab.
Haas M, Lein A, Fuereder T, Schnoell J, Brkic FF, Liu DT, Kadletz-Wanke L, Heiduschka G, Jank BJ. Haas M, et al. Among authors: fuereder t. Invest New Drugs. 2023 Oct;41(5):727-736. doi: 10.1007/s10637-023-01388-x. Epub 2023 Aug 21. Invest New Drugs. 2023. PMID: 37603206 Free PMC article.
Metabolic tumor volume and sites of organ involvement predict outcome in NSCLC immune-checkpoint inhibitor therapy.
Kifjak D, Hochmair M, Sobotka D, Haug AR, Ambros R, Prayer F, Heidinger BH, Roehrich S, Milos RI, Wadsak W, Fuereder T, Krenbek D, Fazekas A, Meilinger M, Mayerhoefer ME, Langs G, Herold C, Prosch H, Beer L. Kifjak D, et al. Among authors: fuereder t. Eur J Radiol. 2024 Jan;170:111198. doi: 10.1016/j.ejrad.2023.111198. Epub 2023 Nov 21. Eur J Radiol. 2024. PMID: 37992608 Free article.
Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial.
Cavalieri S, Bruno E, Serafini MS, Lenoci D, Canevari S, Lopez-Perez L, Hernandez L, Mariani L, Miceli R, Gavazzi C, Pasanisi P, Rosso E, Cordero F, Bossi P, Golusinski W, Dietz A, Strojan P, Fuereder T, De Cecco L, Licitra L. Cavalieri S, et al. Among authors: fuereder t. Front Oncol. 2024 Jan 4;13:1321174. doi: 10.3389/fonc.2023.1321174. eCollection 2023. Front Oncol. 2024. PMID: 38239654 Free PMC article.
Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care center.
Popov P, Steindl A, Wolff L, Bergen ES, Eckert F, Frischer JM, Widhalm G, Fuereder T, Raderer M, Berghoff AS, Preusser M, Kiesewetter B. Popov P, et al. Among authors: fuereder t. Clin Exp Metastasis. 2024 Feb;41(1):25-32. doi: 10.1007/s10585-023-10250-6. Epub 2023 Dec 8. Clin Exp Metastasis. 2024. PMID: 38064128 Free PMC article.
Low free triiodothyronine and immune-related hyperthyroidism are associated with overall and progression-free survival in head and neck squamous cell carcinoma treated with pembrolizumab.
Haas M, Lein A, Fuereder T, Schnoell J, Brkic FF, Campion NJ, Liu DT, Kadletz-Wanke L, Heiduschka G, Jank BJ. Haas M, et al. Among authors: fuereder t. Int Immunopharmacol. 2023 Oct;123:110799. doi: 10.1016/j.intimp.2023.110799. Epub 2023 Aug 21. Int Immunopharmacol. 2023. PMID: 37598631
65 results